Background-In depolarized myocardial infarct epicardial border zones, the cardiac sodium channel is largely inactivated, contributing to slow conduction and reentry. We have demonstrated that adenoviral delivery of the skeletal muscle Na + channel (SkM1) to epicardial border zones normalizes conduction and reduces induction of ventricular tachycardia/ ventricular fibrillation. We now studied the impact of canine mesenchymal stem cells (cMSCs) in delivering SkM1. Methods and Results-cMSCs were isolated and transfected with SkM1. Coculture experiments showed cMSC/SkM1 but not cMSC alone and maintained fast conduction at depolarized potentials. We studied 3 groups in the canine 7d infarct: sham, cMSC, and cMSC/SkM1. In vivo epicardial border zones electrograms were broad and fragmented in sham, narrower in cMSCs, and narrow and unfragmented in cMSC/SkM1 (P<0.05). During programmed electrical stimulation of epicardial border zones, QRS duration in cMSC/SkM1 was shorter than in cMSC and sham (P<0.05). Programmed electrical stimulation-induced ventricular tachycardia/ventricular fibrillation was equivalent in all groups (P>0.05).
R eentry causes most life-threatening cardiac arrhythmias in ischemic heart disease. 1, 2 Antiarrhythmic drugs and surgery terminate reentrant arrhythmias by creating bidirectional conduction block, depressing conduction, and/or prolonging refractoriness. 3 Normalization of conduction in depressed pathways might be an antiarrhythmic alternative to blocking conduction. Yet, the only tools to effect such outcomes have been norepinephrine and acetylcholine, which hyperpolarize cell membranes and whose toxicities render their use here impractical.
Clinical Perspective on p 840
We recently reported a novel means for speeding/normalizing conduction in settings associated with depolarized membrane potentials, leading to low availability of cardiac Na + channels. 4, 5 The skeletal muscle Na + channel (SkM1, Nav1.4) gene has a 10 mV more depolarized midpoint of inactivation 4,5 than the cardiac isoform (SCN5A, Nav1.5). Computer simulations indicated that SkM1 but not SCN5A expression preserves conduction velocity in depolarized environments. 4 When administered via adenoviral vector into ventricular myocardium, SkM1 increases action potential V max and conduction velocity and reduces the incidence of ventricular tachycardia (VT)/ventricular fibrillation (VF) initiated by programmed electrical stimulation (PES) in healing infarcts 4 or occurring spontaneously during ischemia/reperfusion. 5 Because viral gene delivery is not innocuous, 1 objective of the present study was to explore an alternative delivery system. We have successfully introduced hyperpolarizationactivated cyclic nucleotide-gated channel 2 (HCN2), a pacemaker channel gene, into canine myocardium in vivo using adult human mesenchymal stem cells (MSCs) as a delivery platform. Human MSCs express cardiac connexins (Cx40 and Cx43), 6 electrically couple with myocytes, and carrying overexpressed HCN2 channels create biological pacemakers in canine ventricle. 7 These outcomes suggested feasibility of cell-based gene delivery. Therefore, we selected canine MSCs (cMSCs) as a delivery platform in the present study. 8 demonstrated superior effects of SkM1 over SCN5A on V max and conduction in a cell line. We now report the isolation of cMSCs, SkM1 properties in this delivery platform, and their impact on conduction, arrhythmia induction, and action potential V max in healing canine infarcts.
Preliminary in vitro experiments

Methods
Protocols were performed per American Physiological Society recommendations and reviewed and approved by the Columbia and Stony Brook University Institutional Animal Care and Use Committees.
Unless otherwise indicated, chemicals were from Sigma Chemical Co (St. Louis, MO). An expanded version of the Materials and Methods and supporting data is provided in the online-only Data Supplement.
Cell Isolation and Transfection
After euthanasia for other purposes, 4-mL canine bone marrow was aspirated from the iliac crest of 1-year old dogs. cMSC isolation was proceeded by the standard techniques, 9 and transfection of the cells with SkM1 and SCN5A constructs was performed via electroporation using nucleofector technology (Amaxa Lonza, Gaithersburg, MD). Transfection efficiency was 30% to 45%.
In Vitro Studies
Whole-cell patch clamp with a signal amplifier (Model Axopatch-1B; Axon Instruments Inc, Inverurie, Scotland, United Kingdom) was used to measure single cell membrane current. Electrode resistances were 3 to 4 MΩ. The liquid junction potential (≈8 mV between bath and electrode solutions) was not corrected because exchange between pipette and cell is never complete. 10 Neonatal Sprague-Dawley rats were euthanized, and ventricular myocytes were isolated by an approved Stony Brook University Institutional Animal Care and Use Committee protocol as previously described. 11 Isolated ventricular myocytes were replated at 4×10 5 cells per cm 2 for the control group and 3.5×10 5 cells per cm 2 for the coculture groups at a 20:1 ratio, with cMSCs set onto grooved scaffolds. Cultures were maintained for 4 to 5 days before making functional measurements.
For immunocytochemistry, cMSCs were loaded with quantum dots (Qdot 655; Invitrogen, Carlsbad, CA) before coculture. After 4 days of coculture on plastic cover slips, samples were stained with mouse anti-Cx43 (Invitrogen) and rabbit anti-α-actinin (Sigma) and then stained with Alexa 488 and Alexa 546 conjugated secondary antibodies (Invitrogen).
For functional measurements, scaffolds were washed and equilibrated at room temperature and stained with Fluo-4 AM (Invitrogen). A 2-dimensional optical mapping system 12 was used to measure impulse propagation at room temperature.
Canine Studies
cMSCs were prepared as above and used in passages 2 to 4. All batches used had consistently high SkM1 sodium current expression in green fluorescent protein-expressing cells. At the time of in vivo experimentation, cells were thawed, and trypan blue exclusion was used to obtain the percentage and total number of viable cells. 1×10 6 viable cells were suspended in 0.75 mL PBS. The percentage of viable cells was 70% to 90%.
Adult male mongrel dogs (22-25 kg; Chestnut Ridge Kennels, Shippensburg, PA) were anesthetized with thiopental (17 mg/kg IV) and mechanically ventilated. Anesthesia was maintained with isoflurane (1.5%-3.0%). A left thoracotomy was performed by sterile techniques, and coronary ligation was performed as previously described. 13 1×10 6 cMSCs were injected using a 23-gauge needle into 3 sites in the epicardial border zone (EBZ). The injection protocol was similar to that of adenoviral delivery. 4 The chest was closed, and lidocaine (50 μg·kg −1 ·min −1 ) was infused during surgery and for 24 to 48 hours postoperatively. Seven days later, dogs were anesthetized, the heart exposed, and ECGs and electrograms (EGs) acquired, digitized, and stored on a personal computer (EMKA Technologies, Falls Church, VA).
EG recordings, induction of VT, microelectrode studies, infarct sizing, and immunohistochemistry were all performed as previously reported 4 and are detailed in the online-only Data Supplement.
Statistical Analysis
Data are expressed as mean±SEM. For in vitro studies, t tests were used to compare between 2 groups, and Kruskal-Wallis 1-way ANOVA followed by the Dunn multiple comparison test was used to analyze conduction velocity. Arrhythmia incidence in sham and cMSCs or cMSC/SkM1-treated animals was analyzed by Fisher exact test. ECG parameters, EG width recordings, and microelectrode data were analyzed using 1-way ANOVA followed by Bonferroni posttests. During PES at different cycle lengths, QRS duration was analyzed using 2-way ANOVA for repeated measurements. P<0.05 was considered significant.
The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the article as written.
Results
Biophysical Comparison of SkM1 and SCN5A in cMSCs
To study voltage-dependent activation of SkM1 and SCN5A currents in green fluorescent protein-positive cMSCs (n=8 per group), cells were held at −100 mV to prevent inactivation and then pulsed to test potentials from −80 to +40 mV, with 5-mV increments ( Figure 1A ). SkM1 current started activating at −40 mV, was half maximal at −30 mV, and peaked at −20 mV. Comparable SCN5A current measurements were −50 mV, −40 mV, and −25 mV, respectively ( Figure 1C ). This suggests a 5-to 10-mV shift between activation of SkM1 and SCN5A channels. Reversal potentials were at 21.69±1.87 mV and 21.09±3.66 mV, respectively, both close to the Nernst potential for Na + (+23.31 mV at 22°C). Peak current density and peak conductance density were 38.52±4.74 pA/pF and 0.95±0.14 nS/pF for SkM1, respectively, and 55.09±10.60 pA/pF and 1.27±0.27 nS/pF for SCN5A, respectively. There were no significant differences in peak current density or peak conductance density between groups, suggesting comparable expression levels of both genes in cMSCs.
To characterize steady-state SkM1 and SCN5A inactivation, cMSCs were prepulsed for 500 ms to holding potentials from −100 mV to 0 mV, with 5 mV increments, and then stepped to 0 mV ( Figure 1B ). Normalized currents were fitted with the Boltzmann equation. SkM1 channel inactivation had a midpoint of −58.6±0.4 mV and a slope factor of 6.0±0.2 mV. SCN5A had a midpoint of −73.9±0.1 mV and a slope factor of 5.9±0.1 mV ( Figure 1D ). Thus, SCN5A inactivation was ≈15 mV negative to SkM1 (P<0.05). These data confirmed the relatively positive position of SkM1 inactivation voltage dependence, suggesting cMSC/SkM1 may function better to deliver Na + current than cMSC/SCN5A in depolarized cells.
Similar to our human embryonic kidney 239 cell results, 8 time constants for recovery from inactivation of SkM1 and SCN5A in cMSCs are smaller than those for SCN5A at all holding potentials (online-only Data Supplement Figure IV ), especially at more depolarized potentials, suggesting much faster recovery of SkM1 in cMSCs.
cMSCs and cMSC/SkM1 Effects on In Vitro Impulse Propagation
To confirm electrical coupling between cMSCs and cardiac myocytes, we tested SkM1 effects on conduction velocity, with cMSCs as the delivery system in the coculture of myocytes and cMSCs expressing SkM1 on polydimethylsiloxane scaffolds (Figure 2A-2B) . A linear platinum electrode was placed at 1 edge of the scaffold to pace at 1 Hz. Macroscopic optical mapping was carried out at room temperature to record propagation in 2 dimensions. Comparison of conduction velocities among myocyte-only, myocyte-cMSC, and myocyte-cMSC/SkM1 cocultures showed significantly higher conduction velocities in SkM1 cocultures in normal and high K + solutions ( Figure 2C ).
Studies in the Canine Model
Fourteen dogs were injected with cMSCs, 10 with cMSC/SkM1, and 12 were not injected (sham). One cMSC animal died of VT 2 hours after surgery. Two sham animals died of arrhythmias, 1 during surgery and 1 after 2 days. All cMSC/SkM1 animals survived. Animals that died in the first 2 days were excluded from further analysis. We performed terminal experiments at 7 days. During sinus rhythm, ECG cycle length, PR, QT, and QTc did not differ among groups (Table 1) . However, QRS duration in cMSC and cMSC/SkM1 dogs was shorter than sham (P<0.05). EBZ showed broad, fragmented EGs in sham, narrower EGs in cMSC, and narrow and unfragmented EGs in cMSC/SkM1 dogs (Table 1; Figure 3 ). Skeletal muscle Na + channel (SkM1) and SCN5A expression in canine mesenchymal stem cells (cMSCs). A, SkM1 and SCN5A activation in cMSCs held at −100 mV and then pulsed to test potentials from −80 mV to +40 mV, per Methods. B, Inactivation of SkM1 and SCN5A currents in cMSCs held at potentials from −100 mV to 0 mV, with 5-mV increments. C, Current-voltage relationship of SkM1 (n=8) and SCN5A (n=8) in cMSCs, normalized to maximum peak current. D, Inactivation curve (the h ∞ curve) of SkM1 (n=8) and SCN5A (n=8). Data are normalized to the maximum peak current and fit to the Boltzmann equation
where V h is the midpoint membrane potential and K is the slope factor. August 2012
Effective Refractory Period, QRS Duration, and Arrhythmia Incidence During PES
Effective refractory period did not differ among groups ( Table 2 ). During paraseptal site stimulation, QRS duration in cMSC and cMSC/SkM1 dogs was shorter than sham (P<0.05); during EBZ site stimulation, QRS duration was shorter in cMSC/ SkM1 than cMSC or sham dogs (P<0.05; Figure 4 ). Despite the potentially therapeutic actions of cMSC/SkM1 on conduction, sustained VT/VF was induced in 7 of 10 cMSC/SkM1-injected dogs versus 5 of 13 cMSC-injected dogs and 7 of 10 shams (P>0.05).
Microelectrode Studies
After the in situ protocol, tissue slabs of injected regions were used to study the impact of cMSCs and cMSC/SkM1 on EBZ cellular electrophysiology. Resting membrane potential and action potential duration did not differ among groups (P>0.05; Table 3 ). However, V max in cMSC/SkM1-injected preparations was faster than sham and cMSCs (P<0.05; Table 3 ). To provide further insight into the relationship between V max and membrane potential, we plotted them against one another for all groups ( Figure 5 ). This demonstrated that cMSC/SkM1 preparations have faster V max over the full membrane potential range.
Infarct Size, Western Blotting, and Histology
No differences in infarct size were seen among sham, cMSC, and cMSC/SkM1 does (29±2.4, 28±2.1, and 28±3.3%, respectively; P>0.05). Western blotting indicated persistent presence of SkM1 protein in the injection site of cMSC/SkM1-injected animals, whereas the noninjected site in these animals and all tested sites in cMSC or sham-treated animals persistently showed absence of SkM1 protein ( Figure 6A ). Immunohistochemistry of cMSC/SkM1-injected regions demonstrated anti-Cx43 staining at the cMSC and adjacent myocardium interface ( Figure 6B ). SkM1/green fluorescent protein-positive cMSCs were not found in sham EBZ ( Figure 6B ).
Discussion
The present study demonstrates the following: (1) SkM1 biophysical properties in cMSCs are more favorable than SCN5A in restoring fast conduction in depolarized tissue; (2) cMSC/ SkM1 but not unloaded cMSCs maintain relatively fast conduction in depolarized tissue; (3) cMSC/SkM1-injected animals show prominent restoration of fast impulse propagation (narrow EGs, narrow prematurely stimulated QRS complexes, and high V max in excised tissue); (4) despite the potentially therapeutic actions of cellular SkM1 delivery there was no antiarrhythmic effect, contrasting with our previous work using viral delivery 4 ; and (5) whereas prior literature suggests MSC may be proarrhythmic, 14, 15 we found that MSC delivery to a healing canine infarct does not increase VT/VF incidence.
Biophysics of Speeding Conduction Using cMSC-SkM1
Early work on circus movement arrhythmias 16, 17 predicted cessation of reentry if conduction accelerated, such that the activation wave front encountered its own refractory tail. Yet, initial pharmacological strategies to speed conduction (eg, neurohormones) were hampered by proarrhythmia and limited success. 2 Novel drugs (rotigaptide and analogs) 18 and gene therapies 5, 19 provided experimental means to speed conduction by enhancing gap junctional function, but their efficacy is still being debated, 20, 21 and there are concerns that maintaining or increasing gap junctional function during acute infarction will increase infarct size. 19 Cell and gene therapies are being explored as means to prolong effective refractory period and prevent reentry. Cell-based strategies can induce postrepolarization refractoriness, but their antiarrhythmic efficacy is still under investigation. 22, 23 Prolonging repolarization and refractoriness are effective in monomorphic VT, 24 and tachy-pacing induced atrial fibrillation 25 ; efficacy against polymorphic VT/VF is still unknown. Despite concerns regarding proarrhythmia accompanying local prolongation of repolarization, no proarrhythmia occurred in proof-of-concept studies. 24, 25 Ischemic tissue is often depolarized, contributing to reduced Na-channel availability, slow conduction, and reentry. 26, 27 Cardiac Na-channel inactivation is pivotal here 28 and motivated our gene transfer of SkM1 channels whose inactivation kinetics favor current flow in depolarized tissue. 4, 5 These studies showed efficient restoration of conduction and protection against PES-or ischemia/reperfusion-induced arrhythmias.
Concerns regarding use of viral vectors led us to explore alternatives to viral gene transfer. Investigation of biophysical differences between SkM1 and the native cardiac Na-channel SCN5A in cMSCs showed that the midpoint of Na-channel inactivation shifted positively by 15 mV in SkM1-expressing cMSCs compared with cMSC-expressing SCN5A-an outcome similar to results in human embryonic kidney cells and neonatal rat ventricular myocytes. 8, 29 Approximately 60% of SkM1 channels are available at −60 mV, contrasting with <10% of SCN5A channels. Other important predictors of Na + channel availability include fast inactivation and recovery from fast inactivation: both were accelerated in SkM1 versus SCN5A. Together, these results suggest that cellular SkM1 delivery should efficiently restore the pool of available Na + channels in a fashion superior to cellular SCN5A delivery and natively available Na channels.
Efficient coupling of delivery cells (here, cMSCs) to cardiac myocytes via gap junctions is central to ion current delivery. To this end, we previously reported that human MSCs express Cx40 and Cx43, allowing efficient electrical coupling, delivery of overexpressed HCN2 current, and introduction of HCN2-based spontaneous activity in adjacent myocytes. 6, 30, 31 In those studies, HCN2 current and spontaneous activities were blocked by carbonoxalone, highlighting the criticality of gap junctional coupling. To investigate the capability of cMSC/SkM1 to couple to myocytes and speed conduction, we cocultured them with neonatal rat ventricular myocytes. Cx43 was expressed at myocyte/cMSC interfaces, and conduction velocities were increased in normal and depolarized conditions compared with myocyte-only and myocyte/cMSC cell strands (Figure 2 ). This outcome encouraged our in vivo experiments.
Efficient and Specific Restoration of Fast Conduction in Canine EBZ
One concern about the cMSC-based approach was the reduced pH of ischemic tissue, which results in closure of Cx43 gap junctions. 32, 33 This might limit the efficiency of SkM1 current delivery. Despite the potential for suboptimal coupling between myocytes and cMSCs, cMSC-SkM1 efficiently restored fast conduction in EBZ, as evidenced by the following: (1) local EGs in EBZ were broad and fragmented in sham, narrow and less fragmented in cMSC, and narrow and unfragmented in cMSC-SkM1 dogs (Figure 3) ; (2) QRS duration after application of PES in the EBZ was EBZ indicates epicardial border zone; cMSC, canine mesenchymal stem cells; SkM1, skeletal muscle Na + channel; MDP, maximal diastolic potential; and APD, action potential duration.
P<0.05 vs cMSC and sham.
narrow in cMSC/SkM1-injected dogs, comparable with that of uninfarcted dogs; (3) QRS duration was shorter at normal and short coupling intervals in cMSC/SkM1 dogs than in shams or those receiving cMSCs ( Figure 4) ; and (4) V max in isolated EBZ tissues of cMSC/SkM1 was significantly faster than in noninjected or cMSC-injected tissues ( Figure  5 ). These results reflect restoration of fast inward Na current and speeding of conduction in EBZ by cMSC/SkM1, with efficiency comparable with that of viral SkM1. Also similar to viral SkM1 delivery was the lack of proarrhythmia in hearts receiving cMSC/SkM1. Note as well that QT and corrected QT (Table 1) , effective refractory period ( Table 2) , and action potential duration (Table 3) were similar across groups, further illustrating that introducing SkM1 primarily impacts conduction without affecting repolarization. This suggests the outcomes of SkM1-based interventions arise from an effect on conduction.
Absence of Protection Against Inducible VT/VF
Despite the efficacy of cMSC/SkM1 in restoring fast conduction in EBZ, protection against PES-induced VT/VF was not achieved. Several considerations might explain the absence of an antiarrhythmic effect.
First, the extent of speeding of conduction might be insufficient to prevent PES-induced VT/VF. This seems unlikely, as we previously demonstrated significant reduction in the incidence of PES-induced VT/VF with a similar acceleration of conduction based on SkM1 gene transfer. 4 We also showed SkM1 gene therapy speeds longitudinal conduction 34 and prevents ischemia/reperfusion-induced arrhythmias, 5 further supporting the notion that the extent of conduction speeding (similar to viral SkM1) should be antiarrhythmic.
Second, cMSCs could negatively impact conduction by acting as a current sink, 30 thereby slowing conduction and compensating the SkM1 effects. This is unlikely because unloaded cMSCs did not slow conduction. In light of potential current sink effects, it should be noted that we use a small number of cells (≈1 million) because we previously established this dose to generate significant ion channel-based biological function. 7 This dose is much lower than that typically used in studies of cardiac regeneration (≈200 million cells). 35, 36 Third, prior research has shown that MSCs form lowresistance junctions but not intercalated disks with myocytes. 6 Therefore, although conduction is sped by cMSC/SkM1, the organization needed for an antiarrhythmic effect may not be achieved. In addition, it is possible that absence of intercalated disks in the cMSC-SkM1/myocyte unit supports formation and maintenance of reentrant pathways that otherwise would have remained incomplete.
Safety Concerns of MSC-Based Therapies
When considering gene-modified or unmodified MSC transplantation as therapeutic approaches in cardiac disease, 2 concerns have been extensively discussed: (1) the potential of MSCs to be proarrhythmic, 15 and (2) the risk for neoplasia. 37 The proarrhythmia concern is based on studies illustrating slowing of conduction and reentrant arrhythmias in vitro 38 and effective refractory period shortening in vivo 39 after MSC transplantation. However, other in vivo studies report absent 40, 41 or protective 42 effects with regard to ventricular arrhythmias. Our study supplements these findings by showing that transplanting a low dose of allogeneic MSCs into the EBZ is safe and that it improves the conduction properties of the myocardium (Table 1 ; Figure 4 ).
Concern for potential tumorogenesis resulting from MSC transplantation has primarily arisen because even early passage MSCs can manifest chromosomal aberrations. 43 A murine model of MSC transplantation confirmed this concern. 44 Although a large body of literature suggests that the use of human MSCs is safe, 37,42 recent reports of tumor formation in rodents 44 clearly warrant extensive safety analysis of MSC-based therapies.
Study Limitations
In the present study, we asked whether cellular delivery of SkM1 protects against inducible arrhythmias 7 days after myocardial infarction. We worked with a fixed end point (1) because previous research indicated this provides a stable substrate for induction of reentrant arrhythmias, 27 and (2) to allow direct comparison between cellular delivery of SkM1 and previously reported viral delivery. 4 Furthermore, we tested only 1 dose of cells, which had been highly effective in delivering electrical signals locally. 7 Other experiments had indicated that 7 days is sufficient for MSCs to form gap junctions with myocytes and deliver ionic currents. 31 We cannot exclude that a protocol using higher doses or later time points might have had a different outcome. Yet the outcome with the cellular approach, highly efficient normalization of conduction, suggests that sufficient dose and time were available for cellular delivery of SkM1. The lack of specific antiarrhythmic effects of the cMSC/SkM1 intervention suggests that the cell delivery approach was complicated by the mechanistic problems discussed above, rather than resulting from insufficient dose or time.
Conclusions
Using in vitro and in vivo approaches, we have shown that cMSCs provide an efficient platform to control ion channel function in the vicinity of myocardial infarcts. We also have shown that the effectiveness of SkM1-based antiarrhythmic therapy critically depends on the delivery vehicle, with viral gene delivery seeming to be superior. Further attempts to modify conduction in infarcted tissue may, therefore, be better focused on viral delivery of Na + channels, while cells might be reserved for myocardial repair.
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Figure 6.
Western blotting and immunohistochemistry of epicardial border zones (EBZs). A, Western blotting of injection site samples from canine mesenchymal stem cell (cMSC)/skeletal muscle Na+ channel (SkM1)-treated animals showed a specific positive band at 250 kDa comparable to the signal obtained from virally transduced (using an SkM1 adenovirus [Ad-SkM1]) neonatal rat ventricular myocytes (NRVMs) that were used here as a positive control. This 250-kDa SkM1-specific signal was not obtained in tissue from noninjected EBZ of cMSC/SkM1-treated animals nor was it obtained from sham-(not shown) or cMSC-treated animals. GAPDH was used as a loading control. B, In cMSC/SkM1-injected tissue, coimmunohistochemical experiments showed connexin 43 (Cx43; green) on the interface (yellow arrows) between myocardium and SkM1-positive cells. Green fluorescent protein (GFP) is visualized via direct florescence (green) and not optometrically separated from the Cx43 signal. SkM1-positive cells were not detected in sham. Nuclei were counter stained (blue) using 4',6-diamidino-2-phenylindole (DAPI). Scale bar, 25 µm.
